Moleculin Biotech has received Fast Track designation from the US Food and Drug Administration (FDA) for WP1122 to treat Glioblastoma Multiforme (GBM), an aggressive malignant primary brain tumour.
Molecular science and technology company Caris Life Sciences (Caris) and data-driven precision biotherapeutics company Hummingbird Bioscience has announced a strategic collaboration to advance clinical development of latter’s anti-HER3 therapy, HMBD-001.
InnoCare Pharma has received approval from the Health Sciences Authority (HSA) of Singapore for HIBRUKA (orelabrutinib) to treat adult relapsed or refractory mantle cell lymphoma (R/R MCL) patients.
CG Oncology, an oncolytic immunotherapy company, has raised $120m through Series E financing round to advance its lead clinical programmes in bladder cancer towards FDA approval.
A clinical stage biotechnology company Immunomic Therapeutics has received Fast Track Designation (FTD) from the US Food and Drug Administration (FDA) for its ITI-3000 programme to treat patients with Merkel Cell Carcinoma (MCC).
Kite, a Gilead Company, has signed a global license agreement with Refuge Biotechnologies, a synthetic biology company for cancer immunotherapy, for exclusive rights to use latter’s gene expression platform to develop potential treatments for blood cancers.
Gilead Sciences company Kite has secured approval from the European Commission (EC) for Yescarta (axicabtagene ciloleucel) to treat adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL).
Personalis has partnered with Duke University and Olink Proteomics for a research collaboration to study the impacts of immunotherapy on advanced gastroesophageal cancer.
The UK National Institute for Health and Care Excellence (NICE) has recommended pembrolizumab (Keytruda) manufactured by MSD to treat melanoma, the most common form of skin cancer.
NeoImmuneTech (NIT) has received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for NT-I7 (efineptakin alfa) (rhIL-7-hyFc) to treat Glioblastoma Multiforme (GBM), one of the hardest-to-treat cancers.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.